Medicines Manufacturing: Labs of the Future 2026: Up to £1.5 Million for UK SME Automation Projects

Medicines Manufacturing: Labs of the Future 2026: Up to £1.5 Million for UK SME Automation Projects

This Innovate UK competition is aimed at UK businesses that can bring digital, automated, and robotic technologies into medicines development or pharmaceutical manufacturing. The point is not simply to build new software or buy lab equipment. The call is trying to move practical innovations into real pharmaceutical workflows, where they can improve speed, efficiency, and repeatability in work that matters to patients and to the wider medicines supply chain.

The opportunity is open now and closes on 27 May 2026 at 11:00am UK time. If you have a project that can make medicines process development faster, more automated, or easier to scale, this is a serious call worth a close read. It is also a competition with a fairly defined commercial shape: the project must be business-led, UK-based, and sized in a way that suits a medium innovation project rather than a broad research programme.

Key details

What this opportunity is really for

The official description is concise, but the intent is clear: Innovate UK wants projects that help create the “labs of the future” for medicines manufacturing. That means technologies that can change how pharmaceutical process development is done, how manufacturing is run, and how scientists or production teams spend their time.

That focus matters because this is not a generic innovation fund. A strong application should show a direct line from the technology to one or more practical improvements such as:

• shorter development cycles,
• fewer manual steps,
• better data quality,
• more reproducible processes,
• improved decision-making,
• or lower-cost and more scalable manufacturing.

The best fit is usually a company that already has some evidence of feasibility and now needs support to translate that into a usable product, platform, or pilot-ready system. If your project is still very early, too exploratory, or not clearly tied to medicines development or manufacturing, it is unlikely to fit the scope well.

Who should consider applying

The lead applicant must be a UK-registered micro, small, or medium-sized enterprise. If you are applying alone, you must be a UK-registered SME. If you are applying collaboratively, the lead still has to be a UK-registered grant-claiming SME.

That does not mean the project has to stay inside one company. The competition allows collaborations, and the official guidance notes that partners can include businesses of any size, academic institutions, charities, not-for-profit organisations, public sector organisations, research and technology organisations, and Catapults.

This is a useful structure if your idea needs:

• a medicines domain expert,
• a lab or manufacturing test environment,
• access to a healthcare or pharma end user,
• or specialist hardware, regulation, or validation support.

The key is that the lead SME should still own the project direction and have a credible route to commercial use. A common mistake in competitions like this is to present a technically interesting collaboration that never clearly explains who will actually take the solution to market.

What it funds

The official page says UK registered businesses can apply for a share of up to £7.5 million. The broader competition information indicates that individual project grant requests must sit between £500,000 and £1.5 million, and projects should last no longer than 24 months.

That combination suggests a fairly focused innovation window. It is enough to build, integrate, and validate something substantial, but not enough for open-ended R&D. You should therefore think in terms of:

1. a defined technical problem,
2. an implementable product or process change,
3. a test or pilot environment,
4. and a clear route to adoption after the project ends.

The emphasis on digital, automated, and robotic technologies also tells you what the assessors are probably looking for. Ideas might involve machine vision, workflow automation, intelligent control systems, robotics, laboratory orchestration, data pipelines, or related technologies that can materially improve medicines R&D or production. The competition is not asking for a narrow academic paper. It is asking for a deployable industrial advantage.

How the application works

This competition uses the Innovation Funding Service application flow. The application is split into four sections:

1. project details,
2. application questions,
3. finances,
4. project impact.

The project details section is not scored. The scored questions are the heart of the application, and the official guidance is unusually explicit about what each answer should cover. In practice, that means your proposal needs to be written like a business case backed by technical evidence, not like a general grant narrative.

You should also know the process details before you start. The lead applicant is responsible for checking the full submission, making sure all partners complete their sections, and confirming that the application is accurate and eligible. If the application is collaborative, every partner must complete the assigned parts and accept the terms and conditions before submission.

One practical point that applicants sometimes miss: you can reopen the application after submission up until the competition deadline, but you must resubmit it before the deadline or it will not count.

What assessors are likely to care about

The official guidance says five independent assessors review the application, and if you pass the first stage you may be invited to interview. The interview panel will ask you to present the project and answer questions based on what you submitted.

For this competition, assessors are likely to care about four things above all else.

1. Problem fit

You need to show a real medicines manufacturing problem, not just a clever technology. The strongest answers explain the current bottleneck clearly: what slows the process, why current methods are inadequate, and why your approach is better.

2. Practicality

This is a delivery-focused competition. Assessors will want to see that the technology can be used in realistic settings, with a plausible implementation path. They are unlikely to be impressed by a concept that sounds futuristic but has no credible route to integration, validation, or adoption.

3. Commercial relevance

Because the call is led by Innovate UK, the commercial question matters. Who will buy this? Who will use it? What will it save them? Why now? A solid proposal should explain market need, adoption barriers, and why the project can unlock a customer decision.

4. Team capability

The team has to be able to deliver the project and use the result afterwards. That means enough technical depth, enough domain understanding, and enough delivery discipline to finish within the time and budget limits.

How to prepare a strong bid

The best preparation is to reverse-engineer the competition from the assessors’ point of view. Start with the problem, not the idea.

First, write a short paragraph that states the specific medicines manufacturing challenge in plain English. Then explain what the current workaround is and why it is not good enough. Only after that should you describe your solution.

Second, be concrete about the improvement. Instead of saying the project will “transform manufacturing,” explain whether it will reduce cycle time, cut manual handling, improve data traceability, increase throughput, lower failure rates, or make a process more robust. The more measurable the outcome, the better.

Third, show how the project will be validated. If your solution needs a pilot line, a laboratory, a partner site, or integration with existing systems, say so directly. Reviewers do not need a finished product, but they do need confidence that the project can produce evidence by the end of the funding period.

Fourth, think carefully about the finances. A £500,000 to £1.5 million project request is substantial. Assessors will expect the budget to match the work, the timeline, and the expected impact. Too little detail can make a project look undercooked; too much spending for too little evidence can make it look poor value.

Common mistakes to avoid

The most common mistake is scope drift. If your project is about general manufacturing automation, it may not be specific enough. If it is about medicines manufacturing but never explains the medicine-related context, it may look generic. The competition is looking for a clear “labs of the future” use case.

Another common mistake is weak commercial framing. It is not enough to say that the technology is technically interesting. You need to explain who will adopt it, what operational pain it solves, and what market pull exists.

A third mistake is overclaiming. The opportunity is serious, but it is still a project with a defined budget and a 24-month cap. Do not promise full industry transformation if the work package only supports a pilot or proof of concept.

Finally, avoid vague consortium descriptions. If you have partners, explain exactly why they are needed, what they will contribute, and how the collaboration will improve the chance of delivery.

Interview and timing notes

If you are shortlisted, interviews are scheduled between 13 July 2026 and 17 July 2026. The official guidance says the interview presentation should be in Microsoft PowerPoint, no longer than 20 minutes, with no more than 20 slides. You cannot include video or embedded web links.

That means you should prepare as if the interview will be a concise investor-style pitch mixed with technical scrutiny. The panel will likely want to understand:

• the problem,
• the innovation,
• the implementation plan,
• the team,
• the market,
• the risks,
• and the value for money.

You should also be ready to explain how the project would progress after the grant ends. For a competition like this, a good post-project path matters almost as much as the funded work itself.

Useful application checklist

Before you start, make sure you can answer these questions cleanly:

• What exact manufacturing problem are we solving?
• Why is this the right time for the project?
• Why is our team the right lead?
• What evidence do we already have?
• What will be proven by month 24?
• Who will adopt the solution if the project succeeds?
• Why is the requested budget justified?

If any one of those is weak, the application is probably not ready.

FAQ

Is this only for pharma companies?

No. The lead must be a UK-registered SME, and collaborations can include other types of organisations. The key is whether the project clearly supports medicines process development or manufacturing.

Can larger organisations participate?

Yes, but not as the lead applicant. The official eligibility summary allows collaborators of many types, but the lead must be the UK-registered SME.

Is there a fixed award amount?

No single award amount is stated on the main opportunity page. The total competition fund is up to £7.5 million, and the competition guidance indicates project grant requests between £500,000 and £1.5 million.

How long can the project run?

Up to 24 months.

Is collaboration required?

No. The competition is open to single applicants and collaborations.

Official links

• UKRI opportunity page: https://www.ukri.org/opportunity/medicines-manufacturing-labs-of-the-future/
• Find a grant application page: https://www.find-government-grants.service.gov.uk/grants/medicines-manufacturing-labs-of-the-future-1

For applicants who already have a medicines automation or robotics idea, this is the kind of competition that rewards sharp scope, clear validation, and a strong commercial story. If your project can make pharmaceutical work faster, more reproducible, and easier to scale, it is worth taking seriously.